Latham & Watkins is advising Revolution Medicines on the offering, and Davis Polk is advising the underwriters involved.Revolution Medicines, Inc. (Nasdaq: RVMD) has announced the pricing…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
